Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

June 15, 2008 (Vol. 28, No. 12)

Methods for Maximizing Antibody Yields

New Technologies Could Help Usher in Lower Costs and Increased Availability

  • Among recombinant proteins, antibodies stand out as the strongest candidates for new therapeutic drugs and represent the majority of submissions to the FDA and other regulatory agencies. Total sales of recombinant antibodies reached $15.8 billion in 2006 and are projected to go to $28.6 billion by 2010, according to ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.